Zacks: Analysts Expect Rubius Therapeutics Inc (NASDAQ:RUBY) Will Announce Earnings of -$0.57 Per Share

Equities analysts expect Rubius Therapeutics Inc (NASDAQ:RUBY) to post earnings of ($0.57) per share for the current quarter, according to Zacks. Zero analysts have provided estimates for Rubius Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.55) and the lowest estimate coming in at ($0.59). Rubius Therapeutics posted earnings per share of ($0.50) in the same quarter last year, which would suggest a negative year over year growth rate of 14%. The company is expected to report its next earnings report on Tuesday, August 11th.

According to Zacks, analysts expect that Rubius Therapeutics will report full-year earnings of ($2.06) per share for the current year, with EPS estimates ranging from ($2.27) to ($1.52). For the next fiscal year, analysts anticipate that the business will report earnings of ($1.91) per share, with EPS estimates ranging from ($2.38) to ($1.40). Zacks’ EPS averages are an average based on a survey of sell-side research analysts that that provide coverage for Rubius Therapeutics.

Rubius Therapeutics (NASDAQ:RUBY) last announced its earnings results on Monday, May 11th. The company reported ($0.60) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.56) by ($0.04).

A number of analysts have recently commented on the stock. Morgan Stanley cut shares of Rubius Therapeutics from an “overweight” rating to an “equal weight” rating and dropped their target price for the company from $15.00 to $4.00 in a report on Friday, March 13th. Guggenheim dropped their target price on shares of Rubius Therapeutics from $23.00 to $11.00 and set a “buy” rating on the stock in a report on Friday, March 13th. HC Wainwright dropped their price target on shares of Rubius Therapeutics from $40.00 to $28.00 and set a “buy” rating on the stock in a research note on Friday, March 13th. Zacks Investment Research cut shares of Rubius Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, June 4th. Finally, BidaskClub upgraded shares of Rubius Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, April 29th. One research analyst has rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $9.61.

In related news, insider Christina M. Coughlin bought 19,000 shares of the stock in a transaction on Wednesday, April 22nd. The shares were acquired at an average price of $5.52 per share, for a total transaction of $104,880.00. Following the purchase, the insider now owns 19,000 shares of the company’s stock, valued at $104,880. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Pablo J. Cagnoni bought 21,000 shares of the stock in a transaction on Tuesday, April 14th. The shares were bought at an average price of $4.70 per share, for a total transaction of $98,700.00. Following the purchase, the chief executive officer now directly owns 21,000 shares in the company, valued at approximately $98,700. The disclosure for this purchase can be found here. 58.40% of the stock is currently owned by corporate insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Bank of Montreal Can increased its position in shares of Rubius Therapeutics by 45.0% during the 4th quarter. Bank of Montreal Can now owns 4,437 shares of the company’s stock valued at $42,000 after purchasing an additional 1,377 shares during the last quarter. Tower Research Capital LLC TRC increased its position in shares of Rubius Therapeutics by 650.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 6,722 shares of the company’s stock valued at $64,000 after purchasing an additional 5,826 shares during the last quarter. Engineers Gate Manager LP purchased a new stake in shares of Rubius Therapeutics during the 1st quarter valued at about $48,000. Aperio Group LLC purchased a new stake in shares of Rubius Therapeutics during the 1st quarter valued at about $51,000. Finally, BNP Paribas Arbitrage SA increased its position in shares of Rubius Therapeutics by 140.3% during the 1st quarter. BNP Paribas Arbitrage SA now owns 11,523 shares of the company’s stock valued at $51,000 after purchasing an additional 6,727 shares during the last quarter. 93.00% of the stock is owned by hedge funds and other institutional investors.

Shares of RUBY stock opened at $5.98 on Wednesday. Rubius Therapeutics has a 12 month low of $3.35 and a 12 month high of $16.16. The stock has a market cap of $477.22 million, a PE ratio of -2.66 and a beta of 2.35. The company has a current ratio of 8.99, a quick ratio of 8.99 and a debt-to-equity ratio of 0.36. The company’s fifty day moving average price is $6.30 and its 200-day moving average price is $7.27.

About Rubius Therapeutics

Rubius Therapeutics, Inc focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing various RCTs, such as RTX-134 for treatment of phenylketonuria; RTX-Uricase for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; and RTX-OxOx for the treatment of second-line hyperoxaluria.

Featured Article: How Investors Can Profit from Options Trading

Get a free copy of the Zacks research report on Rubius Therapeutics (RUBY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Rubius Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rubius Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.